Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radiotherapy for elderly patients with low-risk breast cancer.
Kaidar-Person O, Poortmans P, Kuten A, Morgan DA. Kaidar-Person O, et al. Among authors: poortmans p. Lancet Oncol. 2015 May;16(5):e196-7. doi: 10.1016/S1470-2045(15)70063-X. Lancet Oncol. 2015. PMID: 25943058 No abstract available.
Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.
Vrieling C, Collette L, Bartelink E, Borger JH, Brenninkmeyer SJ, Horiot JC, Pierart M, Poortmans PM, Struikmans H, Van der Schueren E, Van Dongen JA, Van Limbergen E, Bartelink H. Vrieling C, et al. Among authors: poortmans pm. Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):667-76. doi: 10.1016/s0360-3016(99)00215-1. Int J Radiat Oncol Biol Phys. 1999. PMID: 10524421 Clinical Trial.
The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Van der Hulst M, Van der Schueren E, Bartelink H. Vrieling C, et al. Among authors: poortmans pm. Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):677-85. doi: 10.1016/s0360-3016(99)00211-4. Int J Radiat Oncol Biol Phys. 1999. PMID: 10524422 Clinical Trial.
Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network.
Omlin A, Amichetti M, Azria D, Cole BF, Fourneret P, Poortmans P, Naehrig D, Miller RC, Krengli M, Gutierrez Miguelez C, Morgan D, Goldberg H, Scandolaro L, Gastelblum P, Ozsahin M, Dohr D, Christie D, Oppitz U, Abacioglu U, Gruber G. Omlin A, et al. Among authors: poortmans p. Lancet Oncol. 2006 Aug;7(8):652-6. doi: 10.1016/S1470-2045(06)70765-3. Lancet Oncol. 2006. PMID: 16887482
Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
Goldberg H, Miller RC, Abdah-Bortnyak R, Steiner M, Yildiz F, Meirovitz A, Villà S, Poortmans PM, Azria D, Zidan J, Ozsahin M, Abacioglu U, Gold DG, Amit A, Lavie O, Atahan IL, Kuten A; Rare Cancer Network. Goldberg H, et al. Among authors: poortmans pm. Gynecol Oncol. 2008 Feb;108(2):298-305. doi: 10.1016/j.ygyno.2007.10.037. Epub 2007 Dec 21. Gynecol Oncol. 2008. PMID: 18096209
EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach.
Matzinger O, Gerber E, Bernstein Z, Maingon P, Haustermans K, Bosset JF, Gulyban A, Poortmans P, Collette L, Kuten A. Matzinger O, et al. Among authors: poortmans p. Radiother Oncol. 2009 Aug;92(2):164-75. doi: 10.1016/j.radonc.2009.03.018. Epub 2009 Apr 15. Radiother Oncol. 2009. PMID: 19375186 Review.
Radiotherapy for breast cancer, the TARGIT-A trial.
Yarnold J, Offersen BV, Olivotto I, Poortmans P, Sarin R. Yarnold J, et al. Among authors: poortmans p. Lancet. 2014 May 17;383(9930):1717-8. doi: 10.1016/S0140-6736(14)60828-X. Lancet. 2014. PMID: 24835611 No abstract available.
Haste makes waste: are the data regarding TARGIT-A IORT ready for prime time?
Kaidar-Person O, Poortmans P, Klimberg S, Haviland J, Offersen B, Audisio R, Yarnold J. Kaidar-Person O, et al. Among authors: poortmans p. Breast Cancer Res Treat. 2014 Aug;147(1):221-2. doi: 10.1007/s10549-014-3032-5. Epub 2014 Jul 22. Breast Cancer Res Treat. 2014. PMID: 25048466 No abstract available.
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.
Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, Schinagl D, Oei B, Rodenhuis C, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan D, Dubois JB, Remouchamps V, Mirimanoff RO, Collette S, Collette L; European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Bartelink H, et al. Among authors: poortmans p. Lancet Oncol. 2015 Jan;16(1):47-56. doi: 10.1016/S1470-2045(14)71156-8. Epub 2014 Dec 9. Lancet Oncol. 2015. PMID: 25500422 Clinical Trial.
432 results